Supriya Lifescience Ltd announced an Investor Presentation detailing their audited financial results for Q4 and FY25, showing a 22% revenue increase to INR 2,608.0 million compared to FY24. They reported significant growth in EBITDA and PAT margins as well, reflecting strong performance across various regions.